LHW 090

Drug Profile

LHW 090

Alternative Names: LHV-527; LHW090

Latest Information Update: 04 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Kidney disorders; Resistant hypertension

Most Recent Events

  • 10 Mar 2017 Phase-II clinical trials in Kidney disorders in USA (PO) (NCT02678000)
  • 15 Feb 2016 Novartis Pharmaceuticals plans a phase II trial for Chronic kidney disorders (Treatment-experienced, In adults, In the elderly) in USA, Germany and Romania (PO) (NCT02678000)
  • 01 Nov 2015 Phase-II clinical trials in Resistant hypertension in France (PO) after November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top